Related Experiment Video

Updated: Aug 16, 2025

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.3K

Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

Hongjin Lai1,2, Yi Liu1,2, Juan Wu3

  • 1Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in Pharmacology
|December 22, 2022
PubMed

Insights

Non-steroidal anti-inflammatory drugs (NSAIDs) show promise in preventing and treating cancer by targeting inflammation. Understanding pharmacogenomic variability is key to optimizing NSAID effectiveness for cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Inflammation plays a crucial role in innate immunity and contributes to the development of various cancers, including colorectal, esophageal, and lung cancer.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) are known for their anti-inflammatory properties and are being investigated for their potential in cancer prevention and treatment.
  • Genetic variations among patients (pharmacogenomics) can influence how individuals respond to NSAIDs, impacting their effectiveness and safety.

Purpose of the Study:

  • To review current clinical and experimental research on using NSAIDs to target cancer-related inflammation.
  • To discuss the role and potential of pharmacogenomics in enhancing NSAID-based cancer therapies.
  • To provide insights into the personalized application of NSAIDs for cancer treatment and prevention.

Main Methods:

  • Literature review of clinical and experimental studies.
  • Analysis of pharmacogenomic data related to NSAID efficacy in cancer.
  • Synthesis of current understanding of NSAIDs, inflammation, and cancer.

Main Results:

  • NSAIDs demonstrate potential in reducing cancer risk and improving the efficacy of existing anti-cancer treatments.
  • Pharmacogenomic variability significantly affects NSAID pharmacokinetics and therapeutic outcomes in cancer patients.
  • Targeting cancer-related inflammation with NSAIDs presents a promising strategy, but requires personalized approaches.

Conclusions:

  • NSAIDs hold significant promise for cancer chemoprevention and therapy by modulating inflammation.
  • Pharmacogenomic insights are essential for tailoring NSAID treatments to individual cancer patients for optimal results.
  • Further research into pharmacogenomics will refine the use of NSAIDs in oncology, improving patient outcomes.
Keywords:
cancercyclooxygenaseinflammationnon-steroidal anti-inflammatory drugspharmacogenomics

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

819
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
241
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
4.4K